MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of common stock
$22,000K
Proceeds from the
issuance of debt
$10,000K
Proceeds from the
exercise of stock options...
$510K
Proceeds from the
issuance of common stock...
$404K
Net cash provided by
financing activities
$30,764K
Canceled cashflow
$2,150K
Increase (decrease) in
cash, cash...
$11,914K
Canceled cashflow
$18,850K
Common stock issuance
costs
$1,549K
Debt issuance costs
$520K
Payments on finance lease
liabilities
$81K
Stock-based compensation
expense
$9,131K
Change in fair value of
sepa, warrant and...
-$4,086K
Change in fair value of
contingent earnout...
$2,743K
Trade payables and
accrued liabilities
$2,020K
Amortization of debt issuance
costs
$1,049K
Inventory, net
-$971K
Prepaid expenses and
other assets
-$840K
Pik interest
$800K
Depreciation
$626K
Non-cash lease expense
$429K
Allowance for credit
losses
$163K
Loss on disposal of
property and equipment
-$120K
Deposits
-$5K
Proceeds from disposal of
property and equipment
$80K
Net cash used in
operating activities
-$18,012K
Net cash used in
investing activities
-$838K
Canceled cashflow
$22,983K
Canceled cashflow
$80K
Net loss
-$39,227K
Purchases of property and
equipment
$918K
Accounts receivable
$1,634K
Operating lease
liabilities
-$134K
Back
Back
Cash Flow
source: myfinsight.com
TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc. (TLSI)